Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAMLET: Haploidentical vs Partially Matched Unrelated Donor HCT
NCT03275636Phase 3Completed
- Sponsor
- DKMS
- Start
- Jan 2018
- Primary completion
- Apr 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peripheral blood stem cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) (2 arms), sponsored by DKMS. Primary endpoint: Overall Survival at 2 years. Started Jan 2018; status: completed.
02
Drugs
peripheral blood stem cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03275636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275636.